<DOC>
	<DOCNO>NCT00603967</DOCNO>
	<brief_summary>The primary objective 2-year pilot project test hypothesis skeletal response aromatase inhibitor determine polymorphisms CYP19 gene .</brief_summary>
	<brief_title>Effect Aromatase Inhibitors Bones Genes</brief_title>
	<detailed_description>A family history osteoporosis note . Data factor affect estrogen exposure age menarche , average number period per year reproductive year , number year birth control pill use , total number pregnancy , number pregnancy term , month lactation age menopause record . These data collect baseline . Current medication medical problem record baseline follow-up visit . New medical problem new medication note follow-up . Physical examination do baseline follow-up visit . Body mass index calculate weight ( kg ) divide square height ( m2 ) obtain every visit . Height obtain use standard stadiometer weight take use standard weigh scale . Dietary calcium Vitamin D intake estimate 7-day dietary recall baseline adjust daily intake 1200-1500 mg calcium per day . Vitamin D intake also adjust 800 IU per day . Biochemical Analysis . Routine serum comprehensive metabolic profile ( CMP ) measure standard autoanalyzer technique , serum 25-hydoxyvitamin D double-antibody radioimmunoassay ( Incstar Corp. , Stillwater , Minnesota ) , FSH chemiluminescent assay ( Bayer , NY ) case last menstrual period occur less 12 month sign informed consent . These measurement do Barnes-Jewish Hospital Laboratory . Serum estradiol measure radioimmunoassay ( Diagnostic Systems Laboratories Inc. ) , sex hormone bind globulin double antibody radioimmunoassay ( Diagnostic Laboratories Inc ) . Serum estradiol measurement do Core Laboratory General Clinical Research Center ( GCRC ) Washington University School Medicine sex hormone bind globulin assay do Dr. Villareal 's laboratory . The inter- intra-assay coefficient variation assay &lt; 10 % . In order improve accuracy analysis biochemical test ( except 25-OH Vitamin D ) perform end study run operator plate ( run batch ) . Bone Mineral Density ( BMD ) BMD total body , lumbar spine proximal leave femur measure dual energy X-ray absorptiometry ( DEXA ) use Hologic QDR 4500 ( Hologic Inc. , Waltham Ma , U.S.A. ) . Measurements do month 0 , 6 12 ( see Visits Testing Schedule ) . To guarantee necessary flexibility patient see exact date follow window 1 month earlier 2 month late consider . BMD lumbar spine measure L1 L4 . The non-dominant hip use study proximal femur . The main region interest proximal femur total femur , femoral neck femoral trochanter . The coefficient variability repeat measurement institution is1.09 % lumbar spine 1.2 % total femur center . Bone Turnover Markers obtain month 0 , 6 12 . We follow marker bone resorption ( urine cross-linked N- telopeptide type I collagen [ urine NTx ] , proper 24 hour urine collection do , serum cross-linked telopeptide type I collagen [ serum CTx ) analyze ) one marker bone formation ( serum bone specific alkaline phosphatase { BSAP ) . Due diurnal pattern bone marker , serum specimen collect fast state urinary NTx measure 24-hour urine collection . These marker measure ELISA Core laboratory Clinical Studies Washington University follow : Urine NTX ( Osteomark , Ostex International , Inc. , Seattle , WA ) , serum CTX ( serum crosslaps , Osteometer , Hawthorne , CA ) serum BSAP ( Alkphase-B , Metra Biosystems , Inc. , Mountain View , CA ) . Intra-assay coefficient variation range 4-7 % ( 32 ; 33 ) . In order improve accuracy analysis biochemical test perform end study run operator plate ( conduct batch ) . Vertebral Fracture Evaluation . We evaluate vertebral fracture use vertebral fracture assessment ( VFA ) method perform DEXA machine use measure bone mineral density . Those patient whose VFA suspicious fracture undergo lateral spine X-ray . Vertebral fracture identify visual inspection lateral spine radiograph thoracic lumbar vertebra , T4 L5 . Interpretation radiographs do PI , endocrinologist specialize bone disease Medical Director Bone Health Program Division Bone Mineral Diseases Washington University School Medicine . If PI doubt , easily ask opinion bone radiologists Department Radiology Washington University School Medicine . Menopausal symptom evaluation . Symptoms related menopause evaluate use modify Leuven menopause questionnaire . This straightforward menopause-specific questionnaire cover vasomotor , gynecologic , psychological , cognitive somatic symptom develop validate previous study ( Anti-Cancer Drugs 2004 15:753-760 ) . The Leuven questionnaire include definition menopausal symptom rat : 1 ( symptom ) , 2 ( mild ) 5 ( intolerable ) . This questionnaire administer month 0 , 3 , 6 12 . This questionnaire administer patient visit month 0 , 6 12 , send mail approximately two week prior month 3 . A phone call also make patient prompt complete questionnaire approximately time receive mail ( month 3 ) . Those fail send questionnaire within 1 week indicate date contact phone . A log keep document phone call attempt date mailing document persistence compliance . A symptom score estimate participant . The number symptomatic subject genotype also estimate . Psychometric testing : In current project ass cognitive impairment use mini mental state examination test ( normal range &gt; 72 woman &lt; 8 year formal education &gt; 76 &gt; 9 year formal education ) attention executive function use Trail making test A B ( score number second spent connect 25 numbered circle sequential order [ trail A ] second spent connecting number circle ( 1-13 ) alternately letter alphabet ( A-L ) sequential order [ Trail B ] . In test maximum 180 second allow ) . A fluency test perform ask subject name many animal 1 minute . Additionally Geriatric Depression Scale ( GDS ) perform order exclude assess eventual depression . This test imply 30 question , one correspond score 0 1 . According final score patient classify normal score range 0 9 , mildly depress 10 20 , severely depress score high 20 . These test administer patient visit month 0 , 6 12 . Rationale . To date , 4 polymorphism aromatase gene associate significant difference BMD fracture risk ( 16-18 ) , age-related bone loss ( 18 ; 29 ) also find associate difference breast cancer risk ( 30 ) . Functional in-vitro analysis suggest alter enzymatic activity certain variant gene perhaps account difference risk breast cancer osteoporosis . Variants increase aromatase activity ( 18 ) , high number TTTA repeat , high BMD high risk breast cancer ( 30 ) possibly consequence high estrogen level . Because variant increase enzyme activity , possible select group woman increase sensitivity aromatase inhibition would experience bone loss lower aromatase activity . On contrary , also possible woman variant allele relatively resistant aromatase inhibition compare variant lower enzymatic activity continue synthesize estrogen precursor , therefore , develop rapid bone loss . This proposal address important question compare variant different polymorphism describe .</detailed_description>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Postmenopausal woman age great equal 40 year , least 12 month last menstrual period . For subject amenorrheic &lt; 12 month ( include patient hysterectomy , receive ERT/HRT , render amenorrheic chemotherapy ) , must serum FSH =50 UI/L . Must diagnosis breast cancer stag IIIIA . Planned therapy treatment group must include aromatase inhibitor use third generation nonsteroidal aromatase inhibitor , anastrozole letrozole . Those already treated aromatase inhibitor bone density measurement prior initiation aromatase inhibitor switch tamoxifen third generation aromatase inhibitor also include study . Bone mineral density measurement must range normal osteopenia ( Tscores +2.0/2.0 ) . Those Tscores &lt; 2.0 either lumbar spine femoral neck well history osteoporosisrelated fracture vertebral deformity lateral spine radiograph exclude study . Must ambulatory willing able provide inform consent . No current use medication affect bone metabolism , namely : estrogen , raloxifene , tamoxifen , bisphosphonates , GnRH analogues , glucocorticoid least 5 mg daily 1 month , anabolic steroid dilantin . No evidence diseases know interfere bone metabolism , hyperparathyroidism , hyperthyroidism , osteomalacia , chronic liver disease , renal failure , hypercortisolism , malabsorption , immobilization . No current alcohol tobacco abuse . No evidence bone metastasis evidence abnormal clinical laboratory parameter assess clinically significant investigator .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Aromatase</keyword>
</DOC>